Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05917821 | New Antigens Against Glioblastoma(INAAG) | not yet recruiting | — | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05842746 | Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma | not yet recruiting | Phase 2 | 74 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2023 |
| clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05326334 | THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)(THERABIOME-GBM) | recruiting | — | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT05641220 | Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study.(BIOPSY) | not yet recruiting | — | 325 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05502991 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | not yet recruiting | Phase 2 | 60 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05541042 | Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers | not yet recruiting | — | 50 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04708171 | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections(PROGRAM) | recruiting | — | 453 | Erasmus Medical CenterOTHER | 5 | May 6, 2022 | clinicaltrials |
| NCT03787056 | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients(ONCOPRO) | recruiting | N/A | 410 | Hospices Civils de LyonOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT03005132 | Integrative Analysis of Human Glioblastoma Multiforme | recruiting | — | 1,000 | Shanghai 10th People's HospitalOTHER | 1 | Dec 29, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jul 24, 2023source: clinicaltrials